PetVivo Reports Fiscal Q3 2025 Results
14 févr. 2025 15h10 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Feb. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), a leading biomedical company delivering innovative therapeutics and medical devices for...
PetVivo Signs Exclusive Sales and Marketing Agreement with VetStem for PrecisePRP® Canine and Equine Products
14 févr. 2025 08h00 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, Feb. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), a leader in innovative veterinary medical solutions, has entered into an Exclusive License...
Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
13 févr. 2025 07h00 HE
|
Nutriband Inc.
Partnership Agreement
PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE THIRD QUARTER ENDED DECEMBER 31, 2024
11 févr. 2025 10h15 HE
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Feb. 11, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV and OTCPINK: PETVW), an emerging biomedical device company focused on the commercialization of innovative...
Nutriband Inc. Announces Olympian Anastasia Nichita to Advisory Board
11 févr. 2025 09h00 HE
|
Nutriband Inc.
ORLANDO, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced World and European...
Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™
07 févr. 2025 08h45 HE
|
Nutriband Inc.
U.S. Patent Office issues Notice of Allowance for new patent covering Nutriband's AVERSA™ technology
OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter
29 janv. 2025 08h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic...
PetVivo Engages Former Dechra North American President, Mike Eldred as Commercial and Operations Advisor
27 janv. 2025 09h29 HE
|
PetVivo Holdings, Inc.
PetVivo Board Appoints Eldred as Executive Director to Lead Company Product Commercialization and Operations MINNEAPOLIS, MN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV,...
OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding
22 janv. 2025 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic...
Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025
21 janv. 2025 09h15 HE
|
Dogwood Therapeutics, Inc.
ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid,...